Previous studies from this laboratory have demonstrated that angiotensin II (Ang II) and arginine vasopressin (AVP) are potent hypertrophic agents in cultured rat aortic smooth muscle cells. The present study identified major proteins that accumulate in Ang H-induced and AVP-induced hypertrophic cells and initiated studies of the mechanisms that contribute to their accumulation. Smooth muscle cell hypertrophy induced by Ang H and/or AVP (1 ,uM each) was associated with widespread increases in the content of many cellular proteins that were resolved by one-and two-dimensional gel electrophoresis. However, increases were also selective in nature, with increases in certain individual proteins, including actin (twofold to threefold), vimentin (2.5-fold to sevenfold), tropomyosin (threefold to sixfold), and myosin heavy chain, far exceeding overall increases in cellular protein content (20-40%o). Increases in actin content were due largely to increased expression of smooth muscle ar-actin (3.6to 7.5-fold), as opposed to nonmuscle f-actin (1.7to 2.5-fold). Increases in smooth muscle a-actin were accompanied by a fivefold to eightfold increase in smooth muscle a-actin mRNA, indicating that these changes were not due exclusively to translational controls. Results demonstrate that contractile agonist-induced hypertrophy in cultured smooth muscle cells is due, in part, to increased expression of smooth muscle contractile proteins. Furthermore, the fact that Ang II and AVP induced selective increases in smooth muscle a-actin suggests that these agonists may not only regulate growth of vascular smooth muscle but may also promote expression of smooth muscle-specific contractile proteins during differentiation of vascular smooth muscle. (Circulation Research 1991;68:288-299) Arteries from hypertensive patients and animals have a greater smooth muscle cell (SMC) mass than those of their normotensive counterparts.'-4 Previous studies from this laboratory have demonstrated that the increased SMC mass that occurs in aortas of rats with certain models of experimental hypertension,5-7 although not others,8 was the result of the enlargement of preexisting cells, or SMC hypertrophy, rather than SMC hyperplasia. SMC hypertrophy was often accompanied by DNA synthesis in the absence of cell division, resulting in the development of large numbers of polyploid SMCS.6-7
Mechanisms of Angiotensin II-and Arginine
Vasopressin-Induced Increases Previous studies from this laboratory have demonstrated that angiotensin II (Ang II) and arginine vasopressin (AVP) are potent hypertrophic agents in cultured rat aortic smooth muscle cells. The present study identified major proteins that accumulate in Ang H-induced and AVP-induced hypertrophic cells and initiated studies of the mechanisms that contribute to their accumulation. Smooth muscle cell hypertrophy induced by Ang H and/or AVP (1 ,uM each) was associated with widespread increases in the content of many cellular proteins that were resolved by one-and two-dimensional gel electrophoresis. However, increases were also selective in nature, with increases in certain individual proteins, including actin (twofold to threefold), vimentin (2.5-fold to sevenfold), tropomyosin (threefold to sixfold), and myosin heavy chain, far exceeding overall increases in cellular protein content (20-40%o) . Increases in actin content were due largely to increased expression of smooth muscle ar-actin (3.6to 7.5-fold), as opposed to nonmuscle f-actin (1.7to 2.5-fold). Increases in smooth muscle a-actin were accompanied by a fivefold to eightfold increase in smooth muscle a-actin mRNA, indicating that these changes were not due exclusively to translational controls. Results demonstrate that contractile agonist-induced hypertrophy in cultured smooth muscle cells is due, in part, to increased expression of smooth muscle contractile proteins. Furthermore, the fact that Ang II and AVP induced selective increases in smooth muscle a-actin suggests that these agonists may not only regulate growth of vascular smooth muscle but may also promote expression of smooth muscle-specific contractile proteins during differentiation of vascular smooth muscle. (Circulation Research 1991;68:288-299) Arteries from hypertensive patients and animals have a greater smooth muscle cell (SMC) mass than those of their normotensive counterparts.'-4 Previous studies from this laboratory have demonstrated that the increased SMC mass that occurs in aortas of rats with certain models of experimental hypertension,5-7 although not others,8 was the result of the enlargement of preexisting cells, or SMC hypertrophy, rather than SMC hyperplasia. SMC hypertrophy was often accompanied by DNA synthesis in the absence of cell division, resulting in the development of large numbers of polyploid SMCS. [6] [7] There has been considerable interest in identifying the factors that mediate hypertrophic growth of smooth muscle (SM) in hypertension. One hypothesis is that SM hypertrophy represents an adaptive response to the increased wall stress that accompanies development of hypertension. Whereas there is circumstantial evidence supporting the role for increased blood pressure in mediation of SM hypertrophy,5 there is also evidence that blood pressure changes and SM hypertrophy can be partially dissociated under certain conditions.9,10 Owens5 compared the effects of a variety of antihypertensive drugs on the development of SM hypertrophy and hyperploidy in the spontaneously hypertensive rat.
Results showed that, for a given level of blood pressure lowering, the converting enzyme inhibitor, captopril, was more effective in preventing hypertrophy than was hydralazine, a direct SM relaxant. Results of these studies suggested that hypertrophy was not simply a response to elevated blood pressure and implicated a possible role for angiotensin II (Ang II) in mediation of vascular SMC growth. Furthermore, observations that captopril also reduced aortic SM content in normotensive Wistar-Kyoto rats suggested that Ang II might also play a role in maintenance of vascular mass under normal conditions.
Results of recent studies in cultured SMCs provide further support for the hypothesis that contractile agonists may mediate SM hypertrophy. We"1,12 and others13,14 have shown that the contractile agonists Ang 11 and arginine vasopressin (AVP) stimulated hypertrophy but not hyperplasia of rat aortic SMCs in culture. Contractile agonist-induced increases in protein content of hypertrophied SMCs were concentration dependent, were inhibited by specific receptor antagonists, and were due to an increase in protein synthesis, rather than to a change in the overall rate of protein degradation.1112 However, the cellular mechanisms whereby these contractile agonists increase protein synthesis have not been elucidated. Furthermore, it is not known whether increases in protein content are generalized in nature or restricted to a small subset of cellular proteins and whether changes are mediated at the transcriptional or posttranscriptional level. The major objective of the present study was to elucidate the cellular and molecular mechanisms whereby the contractile agonists Ang II and AVP stimulate increased protein synthesis and hypertrophy of cultured SMCs. Our experimental strategy was first to identify proteins that accumulate in hypertrophic cells and then to initiate studies of the molecular mechanisms that contribute to their accumulation.
Materials and Methods Cell Culture
Rat thoracic aortic SMCs were isolated and cultured as described previously." Cells were grown to confluency, and the growth medium (Medium-199, GIBCO, Grand Island, N.Y.), containing 10% fetal bovine serum (Hyclone Laboratories Inc., Logan, Utah), 100 units/ml penicillin (GIBCO), and 100 ,ug/ml streptomycin (GIBCO), was replaced with serum-free medium (SFM) containing equal parts of Dulbecco's Modified Eagle's medium (GIBCO) and Ham's F12 (GIBCO) supplemented with 1 ,uM insulin (Sigma Chemical Co., St. Louis), 5 ,ug/ml transferrin (Sigma), 0.2 mM ascorbate (Sigma), 100 units/ml penicillin, and 100 ,g/ml streptomycin for 2-3 days to induce quiescence, maintain SMCs in a noncatabolic state for extended periods of time, and promote expression of SM-specific contractile proteins.15-'8 Cell cultures were incubated at 37°C in a humidified atmosphere of 5% CO2-95% 02 with media changes every 2 days.
For the RNA studies, cells were treated for 30 minutes and 4, 8, and 24 hours with 1 ,uM Ang II (Peninsula Laboratories, Inc., Belmont, Calif.), 1 ,uM AVP (Peninsula Laboratories), a combination of 1 ,M each Ang II and AVP, or vehicle (SFM). Cells were then harvested with trypsin-EDTA (0.05% trypsin, 0.02% EDTA; GIBCO), and aliquots were taken for cell counts. After centrifugation, the resulting cell pellet was frozen in liquid nitrogen and stored at -70°C.
Measurements of Protein Content and Synthesis
Sample preparation. For protein and actin content studies, cells were treated for 4 days with 1 ,M Ang II, 1 ,mM AVP, a combination of 1 ,uM each Ang II and AVP, and/or SFM alone (control). Agonists were replenished every day. At harvest, the medium was aspirated; the cell layer was washed twice with icecold phosphate buffered saline containing (mM) NaCl 140, Na2HPO4.7H20 8.1, KCl 2.7, and KH2PO4 1.5 (pH 7.4) and then lysed directly in the culture dish on ice by the addition of isoelectric focusing medium (IEF) containing 1% sodium dodecyl sulfate (SDS), 10% glycerol, and 20 mM dithiothreitol. 19 The dishes were scraped, and the cell lysates were transferred to Eppendorf tubes and sonicated on ice for two or three 10-second bursts. Before freezing and storage at -70°C for two-dimensional electrophoretic analysis, an aliquot was removed for onedimensional electrophoresis and diluted 1:1 with a sample buffer containing 0.1 M Tris, pH 6.8, 1% SDS, 10% glycerol, 0.002% bromphenol blue, and 30 mM dithiothreitol, boiled for 5 minutes, quick-frozen, and stored at -70°C. The DNA content of the samples was determined according to the method of Labarca and Paigen.20 Polyacrylamide gel electrophoresis. One-dimensional SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed as previously described.21
Samples were loaded at approximately 1 ,ug DNA! lane, and care was taken to apply nearly identical amounts of DNA in the experimental and control (SFM) samples to facilitate comparison.
Isoactins and vimentin were resolved by two-dimensional IEF-PAGE22 with a 5-6 pH gradient in the first dimension,21 a 10% slab gel in the second, and a sample load of approximately 500-800 ng DNA. Less abundant cellular proteins were separated by IEF-PAGE using 1.4% pH 4-6.5 and 0.6% pH 6-8 Pharmalyte (Pharmacia LKB Biotechnology Inc., Piscataway, N.J.) in the first dimension and an 11% acrylamide slab gel in the second, with sample loads of approximately 3.5 gg DNA. Gels were stained with Coomassie brilliant blue R and destained. Densitometric analysis was carried out on a Visage 2000 (Biolmage, Ann Arbor, Mich.). Only proteins that were consistently well resolved and reasonably abundant and that showed a well-defined profile were quantitated. The results were expressed as integrated intensity units normalized to total DNA loaded. Because of the inherent variability of global IEF-PAGE, each experimental sample was run in quadruplicate (coefficient of variation was usually less than 10%) and coprocessed with an SFM control sample in quadruplicate. Results were recorded as the means of these determinations, and the data were expressed as percentages of SFM control values.
[35S]Methionine incorporation into proteins. The relative incorporation of [35S]methionine (New England Nuclear, Boston) into proteins was measured as previously described by Blank et al. 23 Between 18 and 24 hours after stimulation with agonist, cells were pulsed with 50 gCi/ml [35S]methionine in medium containing 2 mg/l total methionine. Cells were harvested as described above and subjected to IEF-PAGE at loadings of approximately 300 ng DNA. After staining and destaining, the gels were dried between cellophane and exposed to Kodak X-Omat K film.
RNA preparation. RNA was extracted by the guanidium isothiocyanate/CsCl method. 24 Extracted RNA was dissolved in sterile water, and concentration was measured spectrophotometrically. The samples were stored at -70°C until use. Dot blots were prepared by dissolving 2 gg total RNA in 1 ml of 25 mM NaPO4, pH 7.2, and applying this RNA in twofold serial dilutions to a Nytran membrane (Schleicher and Schuell. Inc., Keene, N.H.) equilibrated with the same buffer. The blot was then treated with ultraviolet radiation.
Actin isoform-specific probes and blot hybridization. SM a-actin mRNA was measured using a 191-bp 3'-untranslated region probe generated in our laboratory by nested deletions of a near-full length SM a-actin cDNA (from a rat stomach cDNA library) provided by K. McHugh and J. Lessard, Children's Hospital Research Foundation, Cincinnati, Ohio.
This probe reacts specifically with SM a-actin based on Northern analysis. 25 The SM a-actin cDNA probe was labeled by cRNA synthesis in the presence of [a-32P]CTP (Riboprobe, Promega Corp., Madison, Wis.). Blots were hybridized and washed as previously described. 25 Nonmuscle ,B-actin was measured using a specific probe that was made isotype specific by removal of all but the 3' untranslated region by exonuclease III digestion of a full-length nonmuscle /-actin cDNA obtained from a rat aorta cDNA library constructed in our laboratory.25 This probe was labeled with [a-32P]dCTP by random priming (PrimeTime, International Biotechnologies, Inc., New Haven, Conn.) and hybridized and washed by the method of Church and Gilbert. 26 The filters were dried and exposed to Kodak X-Omat K Film at -70°C in the presence of an intensifying screen. The optical densities of hybridization signals on x-ray films were measured using a video digitizer attached to an IMB-PC-type microcomputer running customized image analysis software. Only those dots that were in the linear response range of the film were used in quantitation. Absorbance units are expressed as a fraction of RNA concentration.
Statistics
All results were analyzed by either Student's t test or an analysis of variance combined with the Newman-Keuls multiple-range test for intergroup comparisons. Values ofp.0.05 were interpreted as being statistically significant. Data reported in the text are mean+SD.
Results

Ang II and AVP Elicit Widespread but Selective Increases in Protein Content
Our initial aim was to identify proteins that accumulate in hypertrophic cells and to compare the magnitude of increases in these proteins with overall increases in protein content. To determine whether changes in protein content were generalized or specific, we performed one-and two-dimensional electrophoretic analyses. Only those proteins (gel spots) that were consistently well resolved and abundant and that showed a well-defined profile were considered for analysis. Of those proteins, a group was selected randomly to eliminate bias. Results demonstrated that the content of most proteins that were resolvable by one-dimensional gel electrophoresis Figure 1 showing effect of angiotensin II (AII) and/or arginine vasopressin (AVP) on cellular protein content and distribution. OD, optical density; SFM, serum-free medium.
was increased in Ang Il-treated and AVP-treated cells (Figures 1 and 2 ). For example, the content of six proteins in groups treated with Ang II, AVP, and Ang II+AVP (Figure 2 ; bands were located at posi- Whereas one-dimensional electrophoretic analysis has the advantage of representing most, if not all, cellular proteins, it provides poor resolution of individual proteins (i.e., many proteins may migrate within a single band). Thus, to further evaluate the nature of protein changes in agonist-treated SMCs, *~AV P pH 4-6.5 and 0.6% pH 6-8 Pharmalyte in the first dimension and 10% acrylamide slab gel in the second dimension) showing the effect of angiotensin II (AII) and/or arginine vasopressin (AVP) on cellularprotein content and distribution (upper three panels). Postconfluent. quiescent rat aortic smooth muscle cells were treatedfor 4 days with AII (1 pM), AVP (1 pM), AlI +A VP (1 pM each; gel not shown). Control cells were kept in serum-free medium (SFM). Approximately equal amounts of DNA were loaded onto each gel (SFM, 3.68 pg DNA; AII, 3.56 pg DNA; AVP 3.56 pg DNA; AII+AVPF 3.46 pg DNA). The schematic (bottom panel) shows the location of11 selectedproteins, as well as vimentin (V), tropomyosin (TM), and the isoactins, which were quantitated by densitometric analysis. For technical reasons, only proteins that were well resolved and reasonably abundant and that showed a well-definedprofile could be quantitated. The 11 proteins analyzed were randomly selectedfrom this subgroup.
two-dimensional gel electrophoretic analyses were performed to better resolve individual proteins. Consistent with results of one-dimensional gels, exami- 4 ) likewise indicated that the content of many proteins was increased in cells treated with Ang II, AVP, and Ang II+AVP. To confirm impressions based on visual observations, densitometric analysis was performed on 11 randomly chosen proteins selected on the basis of the following criteria: 1) only proteins that were well resolved, and with well-defined profiles, were selected to ensure the accuracy of densitometric analysis, and 2) reasonably abundant proteins were chosen to ensure that the proteins examined actually contributed significantly to cell hypertrophy. Results demonstrated that the content of all but one protein (protein 1 in AVP-treated cells) was significantly increased in cells treated with AVP or the combination of Ang II and AVP as compared with SFM controls. In contrast, the content of only five of the 11 proteins examined was significantly increased in Ang Il-treated cells. The biological significance of the differences between Ang II and AVP are obscure, since proteins that increased with AVP and not with Ang II showed modest changes. Thus, our emphasis will be on proteins that show large changes, since further investigation of these is much more likely to provide definitive insight into the mechanisms responsible for agonist-induced hypertrophy. For example, increases in certain proteins, including protein 6 (800% increase with AVP) and protein 9 (500% increase with AVP), far exceeded overall increases in cellular protein content, which ranged between 20% and 40%.11,12 These results indicate that agonist-induced increases in protein content are widespread but also somewhat selective in nature.
Ang II and AVP Elicit Increases in Actin, Vimentin, and Tropomyosin Content The preceding results showed an overall, yet selective, increase in many proteins that were easily resolved using one-and two-dimensional electropho-resis. However, a number of major contractile and cytoskeletal proteins, including the most abundant protein in these cells, actin, were not resolved on the broad pH range gels used in the preceding analyses. To evaluate these proteins, we extended our analyses to include a gel electrophoresis with a narrow pH range. Results demonstrated that chronic treatment of cells with Ang II and AVP significantly increased the content of actin (twofold to threefold), vimentin (2.5-fold to sevenfold), and tropomyosin (threefold to sixfold) ( Figures 5 and 6 ). Significantly, the Ang Il-induced and/or AVP-induced increases in these proteins far exceeded increases in overall cellular protein content. In addition, agonist-induced increases in SM a-actin (Ang IL, 3.6-fold; AVP, 7.5fold; Ang I+AVP, 6.8-fold) were much greater (p<0.05) than those for nonmuscle j3-actin (Ang LI, 1.7-fold; AVP, 2.4-fold; Ang II+AVP, 2.5-fold), y-actin (Ang II, 2.1-fold; AVP, 2.9-fold; Ang II+AVP, 3.3-fold), and total actin (Ang II, 2.0-fold; AVP, 3.2-fold; Ang II+AVP, 3.0-fold). Ang IL and AVP also elicited marked increases in vimentin (Ang II, 2.6-fold; AVP, 5.9-fold; Ang II+AVP, 6.9-fold) and tropomyosin (Ang II, 3.1-fold; AVP, 6.2-fold; Ang II+AVP, 6.3-fold). Consistent with previous results,12 cotreatment of cells with Ang II and AVP resulted in an increase in protein content equal to or greater than that for either agonist alone, although effects were neither additive nor synergistic.
Ang II and AVP Elicit Widespread but Selective Increases in Protein Synthesis
Taken together, the preceding results indicate that Ang lI-induced and/or AVP-induced SMC hypertrophy is the result of widespread but selective increases in the content of individual proteins. To determine whether there was a corresponding increase in synthesis of individual proteins, SMCs were treated as in the preceding studies but were pulsed with [35` ]methionine between 18 and 24 hours after treatment; this procedure was followed by autoradiographic analysis of proteins resolved by global two-dimensional gel electrophoresis. Results demonstrated that treatment of cells with Ang II and AVP appeared to increase the synthesis of all of the proteins that could be resolved on autoradiographs (Figure 7) , including each of the 11 proteins analyzed previously. The percent increase in protein synthesis appeared to vary between proteins. For example, [35S]methionine incorporation into proteins 5 and 6 was much less than that for proteins 2 and 8. Densitometric analysis of actin synthesis23 showed a threefold to fourfold increase in synthesis (data not shown), thus confirming impressions based on visual comparisons. This elevation in actin synthesis, as well as content (twofold to threefold), far exceeded that for total protein synthesis and content.1"12 These results, as well as the fact that actin is one of the most abundant proteins in vascular SMCs,27 indicate that actin, and specifically SM a-actin, is one of the major proteins that accumulates in Ang II-treated and AVP-treated SMCs.
It is possible that the increase in [35S]methionine incorporation ma; represent an increase in the specific activity [ 5S]methionine in the precursor pool rather than an actual increase in protein synthesis. However, this seems unlikely for the following reasons: 1) the steady-state specific activity of labeled amino acids is unlikely to be affected by agonists, 2) the relatively long labeling period (hours) should minimize the effects of agonists on the equilibration time (minutes) of labeled amino acids between the extracellular and intracellular amino acid pools, and 3) the overall rates of protein synthesis are known to be increased in Ang IItreated and AVP-treated SMCs. 11, 12 Effects ofAng II and AVP on Actin Isoform mRNA Levels
The preceding results showed that an increase in actin content, as well as synthesis, contributed significantly to agonist-induced hypertrophy (Figures 5  and 6 ). As a first step in the determination of the molecular mechanisms responsible for this accumulation of actin, dot blot analyses of SM a-actin (Figures 8 and 9 ) and nonmuscle f8-actin mRNA levels (Figures 10 and 11 ) were performed. Ang II and/or AVP treatment induced a marked increase in SM a-actin mRNA levels. Maximal effects were observed 8 hours after agonist stimulation (Ang II, fivefold increase; AVP, eightfold increase). Ang II and/or AVP also induced an increase in nonmuscle ,3-actin mRNA levels (at 8 hours: Ang II, -threefold increase; AVP, -fourfold increase), although increases were considerably less than those observed for SM a-actin. These results are consistent with those from gel electrophoretic analyses showing that Ang II and AVP elicited significantly greater increases in SM a-actin content as compared with nonmuscle ,-actin and y-actin.
Discussion
Previous studies from this laboratory1""2 have demonstrated that contractile agonists are potent hypertrophic agents but have no detectable mitogenic activity in cultured rat aortic SMCs. The principal aim of the present study was to identify those proteins that accumulate in hypertrophic cells and subsequently to determine the mechanisms responsible for their accumulation. Results demonstrated that Ang lI-induced and/or AVP-induced SMC hypertrophy was associated with a widespread but selective increase in the content of a number of abundant cellular proteins (Figures 1-4) . Significantly, increases in actin, as well as a number of other proteins, far exceeded overall increases in cellular protein (Figures 5 and 6 ). Increases in actin content were associated with a corresponding increase in actin synthesis as well as mRNA content ( Figures  8-11 ), thus indicating that Ang lI-induced and AVPinduced hypertrophy was not due exclusively to translational controls. This observation is important since it demonstrates that further investigation of the molecular mechanisms whereby Ang II and AVP increase SM a-actin gene expression will provide important insight regarding how these agonists induce SMC hypertrophy. Whereas major changes in certain proteins occurred in response to Ang II and/or AVP treatment, these contractile agonists also induced smaller increases in many other proteins, suggesting that agonists may also stimulate general changes in protein synthesis via translational controls.
The overall increase in cellular protein synthesis and content in response to Ang II and AVP may be due to an overall increase in the synthesis of rRNA. There is precedence for this in that cardiac hypertrophy both in vitro and in vivo is mediated, at least in part, by an increase in the synthesis of ribosomal RNA.28,29 Several studies30-32 have demonstrated that Ang II, after either internalization or generation within the cytoplasm, can act directly on the nucleus. Furthermore, Re and Parab32 showed that Ang LI, but not saralasin, significantly increased RNA synthesis in hepatic nuclei. The stimulation of RNA synthesis by Ang II observed by these investigators was sensitive to a-amanitin, a selective RNA polymerase IL inhibitor, suggesting that these effects are dependent on transcription of mRNA. Studies by Re et a130 also suggested that Ang II binding to active regions of native chromatin appeared to induce a conformational change that enhanced the accessibility of DNA to RNA polymerase, thereby increasing RNA initiation sites. These studies raise the possibility that internalization and subsequent binding of Ang IL to nuclear receptors may play a role in mediation of its long-term hypertrophic effects in vascular SMCs. However, an alternative possibility is that Ang II may increase overall rates of protein synthesis via translational controls. Ang II has been shown to increase S6 kinase activity in cultured rat aortic SMCs,14 and there is evidence that S6 kinasemediated phosphorylation of the ribosomal protein S6 plays an important role in mediation of growth factor-induced increases in protein synthesis. 33 Ang II and AVP also induced selective increases in the synthesis and content of certain proteins that far exceeded increases in overall protein synthesis and content. These results indicate that selective increases in gene expression also contributed to agonist-induced cellular hypertrophy. Results showing that agonists increased SM a-actin mRNA levels by fivefold to eightfold within 8 hours of treatment provide direct evidence that this is indeed the case. Agonist-induced increases in SM a-actin mRNA may be the result of an increase in the rate of gene transcription, an increase in the efficiency of processing of the primary transcript, and/or increased stability of the mature mRNA. Whereas there is no direct evidence in this regard, Berk et a113 showed that Ang Il-induced increases in protein synthesis were blocked by the transcriptional inhibitor, actinomycin D. In addition, we found that Ang II-induced and AVP-induced increases in protein synthesis were inhibited by a-amanitin, the transcriptional inhibitor that selectively inhibits mRNA synthesis (A.A.T. Geisterfer and G.K. Owens, unpublished observations). These results suggest that Ang IT-stimulated increases in protein synthesis are transcriptionally FIGURE 6. Histogram showing the effect of chronic angiotensin II (AI) and/or arginine vasopressin (AVP) treatment on the content of specific cytoskeletal and contractile proteins. The results are from the densitometric analysis of gels shown in Figure 5 . Six experimental samples were run in quadruplicate and coprocessed with a serum-free medium (SFM) control sample that was also run in quadruplicate. Results were recorded as mean±SD of these determinations. Alpha, smooth muscle a-actin; beta, nonmuscle /-actin; gamma, smooth muscle plus nonmuscle y-actins; TM dependent. However, one must cautiously interpret results from studies using transcriptional inhibitors because of the nonspecific actions of these drugs and particularly because of the drug-induced depletion of some of the components, such as certain proteins and ribosomal subunits, that comprise the protein synthetic machinery of the cell. Thus, it remains to be determined whether agonist-induced increases in SM a-actin mRNA are mediated transcriptionally or posttranscriptionally. Several investigators131444 -36have examined the role of early signal transduction pathways and second messengers in mediation of Ang Il-induced hypertrophy. Ang II induces phospholipase C-mediated hydrolysis of membrane phosphoinositides, which is coupled with the activation of protein kinase C and calcium mobilization in rat vascular SMCs.34,37-39 Berk et al13 demonstrated that Ang Il-induced increases in protein syn-thesis could be markedly inhibited by buffering agonistinduced changes in intracellular calcium. Whereas these results show that agonist-induced increases in protein synthesis are calcium dependent, treatment of SMCs with the calcium ionophore, ionomycin, did not stimulate protein synthesis,13 suggesting that calcium may play a permissive rather than regulatory role in mediation of Ang Il-stimulated protein synthesis. Berk et a113 also presented evidence suggesting that Ang Il-induced increases in protein synthesis were not dependent on activation of protein kinase C.
A major limitation in investigations of the role of second messenger systems in the hypertrophic response is that it is difficult to' show direct causal relations between the early change in the second messenger system and a relatively long-term change in protein metabolism. Experimental manipulations of second messenger systems are likely to have direct effects on tion. Furthermore, one must demonstrate that the proteins that contribute to the early increases in protein synthesis actually contribute to the protein accumulation that accounts for the cellular hypertrophy. For these reasons, our experimental approach was first to identify proteins that accumulate in hypertrophic cells 0 c 0 IL Ui) 0 0 and then to begin to examine the molecular mechanisms that contribute to their accumulation. There is also evidence suggesting that Ang II and/or AVP may exert their hypertrophic effects via activation of proto-oncogenes, which have been implicated in growth regulation. 40 induction of the proto-oncogenes c-fos34,36M43 and c-myc. 35 The Ang lI-induced increases in c-fos and c-myc were dose dependent and dose specific (competitively inhibited by saralasin) and were independent of protein synthesis. Kawahara gene through the activation of protein kinase C and calcium mobilization in cultured vascular SMCs. It is possible that the protein products of these genes may mediate the effects of Ang II on cell growth. However, the function of the protein products of these genes, under normal or hypertrophic conditions, is SFM 0a All * AVP All + AVP FIGURE 11 . Histogram showing the effect of angiotensin II (AII) and/or arginine vasopressin (A VP) on nonmuscle ,B-actin mRNA levels. The results are from the densitometric analysis ofdot blots shown in Figure 10 . Values represent mean±SD of two or three evaluations of each sample. These results are representative of two independent experiments. SFM, serum-free medium. still unclear,44 and there is currently no direct evidence that they play a role in Ang II-induced and AVP-induced SMC hypertrophy. Ang II and AVP stimulated selective increases in the SM-specific contractile protein, SM a-actin, suggesting that contractile agonists may also act as important positive regulators during differentiation of SM. In contrast, the potent SM mitogen, plateletderived growth factor (PDGF), induces a rapid and dramatic decrease in SM a-actin expression.23 '25 The three isoforms of PDGF appear to have differential effects on SM a-actin expression.23,25'45 As with platelet PDGF25 (comprised mostly of PDGF AB), PDGF BB elicits dramatic decreases in SM a-actin mRNA levels. 45 In contrast, PDGF AA induced increased expression of SM a-actin. 46 Ang II treatment of cultured rat aortic SMC induced transcription-dependent increases in expression of PDGF A-chain mRNA and PDGF secretion into the media. 35 This increase occurs after approximately 6 hours of Ang II stimulation and requires protein synthesis. In contrast, no PDGF B-chain mRNA was detected. These results give rise to the possibility that Ang I-induced increases in protein synthesis and cellular hypertrophy, as well as SM a-actin expression, may be mediated by PDGF AA. In summary, results of the present studies demonstrated that Ang Il-induced and/or AVP-induced SMC hypertrophy is associated with a widespread but selective increase in the content of high abundance cellular proteins. Increases in actin content far exceeded overall increases in cellular protein and were accompanied by a corresponding increase in SM a-actin mRNA. Results indicate that agonist-induced hypertrophy was not due exclusively to translational controls. However, the global nature of agonistinduced increases in protein synthesis suggests that agonists may also stimulate general changes in protein synthesis via translational controls. Additional studies will be required to directly address this issue, as well as to determine whether mRNAs for contractile proteins other than actin are also increased and whether these changes are mediated transcriptionally or posttranscriptionally. In any event, it appears likely that further studies of the mwchanisms whereby contractile agonists increase SM a-actin expression will provide important insight regarding the molecular mechanisms responsible for contractile agonistinduced SMC hypertrophy.
